• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infect Dis (Auckl) . Prolonged Viral Shedding in Patients with Mild to Moderate COVID-19 Disease: A Regional Perspective

tetano

Editor, Senior Moderator
Infect Dis (Auckl)


. 2021 Apr 13;14:11786337211010428.
doi: 10.1177/11786337211010428. eCollection 2021.
Prolonged Viral Shedding in Patients with Mild to Moderate COVID-19 Disease: A Regional Perspective


Mehrab E Hossain[SUP] 1 [/SUP], David Lister[SUP] 1 [/SUP], Caroline Bartolo[SUP] 1 2 [/SUP], Paul M Kinsella[SUP] 3 [/SUP], James Knox[SUP] 3 [/SUP], Rosemary Aldrich[SUP] 4 [/SUP], Raquel Cowan[SUP] 1 2 [/SUP], Robert J Commons[SUP] 1 5 [/SUP]



Affiliations

Abstract

Background: The risk of transmission of Coronavirus Disease 2019 (COVID-19) is increasingly understood to be greatest early after symptom onset, however, factors associated with prolonged and increased risk of transmission remain unclear. In settings where COVID-19 prevalence is low, there may be a benefit of extending the period that patients are isolated to decrease the risk of transmission. This study explored the duration of viral shedding in such a location, in patients with mild-moderate COVID-19 disease in Ballarat, Australia.
Methods: Patients diagnosed with COVID-19 disease using a real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay from oropharyngeal and bilateral deep nasopharyngeal sampling and managed through Ballarat Health Services between March 1 and May 1, 2020 were included. Patients were retested if they were afebrile for >72 hours, asymptomatic and >14 days since symptom onset. If positive on retesting, patients were tested every 3 to 7 days thereafter.
Results: Patients underwent testing a median of 4 days (range 1-12) after initial symptom onset. Duration of symptoms ranged from 1 to 36 days. Positive tests were recorded up to a median of day 21 (range 6-38). Cycle thresholds were inversely correlated with time since symptom onset (P < .0001). Median time to the first negative test was 25 days (range 12-32). Two patients who had remained asymptomatic for >7 days after initial symptom onset had recrudescence of mild symptoms on day 13 and 14; both tested positive on follow-up tests at this time.
Conclusions: This study demonstrates prolonged shedding of COVID-19 in patients with mild-moderate disease. It suggests that some patients with mild disease may have recrudescence of symptoms a week or more after their initial symptoms resolved.

Keywords: Australia; COVID-19; SARS-CoV-2; mild; shedding.
 
Back
Top Bottom